Shire PLC’s “Buy” Rating Reaffirmed at Jefferies Group (SHP)
Shire PLC (LON:SHP)‘s stock had its “buy” rating reaffirmed by equities researchers at Jefferies Group in a research report issued on Tuesday, AmericanBankingNews.com reports. They currently have a GBX 3,400 ($56.98) price objective on the stock. Jefferies Group’s price objective would indicate a potential upside of 3.41% from the stock’s previous close.
SHP has been the subject of a number of other recent research reports. Analysts at Cenkos Securities Ltd reiterated a “buy” rating on shares of Shire PLC in a research note on Monday. They now have a GBX 3,703 ($62.06) price target on the stock. Separately, analysts at Credit Suisse raised their price target on shares of Shire PLC from GBX 3,200 ($53.63) to GBX 3,400 ($56.98) in a research note on Friday. They now have a “neutral” rating on the stock. Finally, analysts at Citigroup Inc. raised their price target on shares of Shire PLC from GBX 3,200 ($53.63) to GBX 3,600 ($60.33) in a research note on Wednesday, February 12th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. Shire PLC currently has an average rating of “Buy” and a consensus price target of GBX 2,607.99 ($43.71).
Shire PLC (LON:SHP) traded up 1.17% on Tuesday, hitting GBX 3288.00. The stock had a trading volume of 1,893,364 shares. Shire PLC has a 52 week low of GBX 1853.0001 and a 52 week high of GBX 3294.00. The stock’s 50-day moving average is GBX 3007. and its 200-day moving average is GBX 2702..
Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.